GSK upgraded at Berenberg on growth outlook
Berenberg upgraded GSK NYSE:GSK to Buy From Hold, saying the company is undervalued and its "heavy discount to peers is no longer justified."The firm increased its price target to £22 from £20 (~19% upside based on Sept. 14 close on the London Stock Exchange).Analyst Kerry Holford said that while G…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.